Cargando…
Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival
Breast cancer (BC) patients with a germline CHEK2 c.1100delC variant have an increased risk of contralateral BC (CBC) and worse BC-specific survival (BCSS) compared to non-carriers. We aimed to assess the associations of CHEK2 c.1100delC, radiotherapy, and systemic treatment with CBC risk and BCSS....
Autores principales: | Morra, Anna, Schreurs, Maartje A. C., Andrulis, Irene L., Anton-Culver, Hoda, Augustinsson, Annelie, Beckmann, Matthias W., Behrens, Sabine, Bojesen, Stig E., Bolla, Manjeet K., Brauch, Hiltrud, Broeks, Annegien, Buys, Saundra S., Camp, Nicola J., Castelao, Jose E., Cessna, Melissa H., Chang-Claude, Jenny, Chung, Wendy K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Journal Experts
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949248/ https://www.ncbi.nlm.nih.gov/pubmed/36824750 http://dx.doi.org/10.21203/rs.3.rs-2569372/v1 |
Ejemplares similares
-
Genetic modifiers of CHEK2*1100delC associated breast cancer risk
por: Muranen, Taru A., et al.
Publicado: (2016) -
Association of the
CHEK2
c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer‐specific survival
por: Morra, Anna, et al.
Publicado: (2023) -
CHEK2 1100delC in patients with metachronous cancers of the breast and the colorectum
por: Isinger, Anna, et al.
Publicado: (2006) -
Genomic profiling of CHEK2*1100delC-mutated breast carcinomas
por: Massink, Maarten P. G., et al.
Publicado: (2015) -
CHEK2
(∗)1100delC Mutation and Risk of Prostate Cancer
por: Hale, Victoria, et al.
Publicado: (2014)